Leading the way to safer medication
 Crosscheck  Recommender

ABEVMY

Found in: Lithuania

Active ingredients

#
Active Ingredient
Description
1
Bevacizumab

Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.

Medicine classification

ATC Code
Title
Class
L01FG01
Bevacizumab
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors

Identifiers

Authority
Identifier(s)
Valstybinė vaistų kontrolės tarnyba (LT)
Identifier(s): 1092483, 1092484, 1092485, 1092486, 1092487